Nurix Therapeutics (NRIX) EBT Margin (2019 - 2026)

Nurix Therapeutics (NRIX) has reported EBT Margin for 8 consecutive years, with 993.1% the latest figure, recorded in Q2 2026.

• In Q2 2026, EBT Margin fell 89617.0% year-over-year to 993.1%; the TTM figure through May 2026 stood at 931.29% (down 69767.0% YoY), while the FY2025 annual figure was 314.0%, up 4036.0% from the prior year.
• EBT Margin improved to 993.1% in Q2 2026 per NRIX's latest filing, from 1406.73% in the prior quarter.
• Across five years, EBT Margin topped out at 79.14% in Q2 2023 and bottomed at 1406.73% in Q1 2026.
• Historically, EBT Margin has averaged 486.01% across 5 years, with a median of 392.7% in 2022.
• Annual changes were most pronounced in 2023 — EBT Margin surged 41196 bps — and 2026, when it sank 110136 bps.
• Nurix Therapeutics' EBT Margin stood at 688.74% in 2022, then surged by 60 bps to 276.77% in 2023, then plunged by 59 bps to 440.69% in 2024, then tumbled by 31 bps to 576.13% in 2025, then sank by 72 bps to 993.1% in 2026.
• Business Quant data shows NRIX's EBT Margin at 993.1% in Q2 2026, 1406.73% in Q1 2026, and 576.13% in Q4 2025.